Evaluation of novel particles as pulmonary delivery systems for insulin in rats

Garcia-Contreras L, Sarubbi D, Flanders E, et al. Immediate and short-term cellular and biochemical responses to pulmonary singledose studies of insulin and H-MAP. Pharm Res. 2001;18(12):1685–1693.

Suarez S, Garcia-Contreras L, Sarubbi D, et al. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm Res. 2001;18(12):1677–1684.

Pohl R, Muggenburg BA, Wilson B, Woods RJ, Burrell BE, Steiner SS. A dog model as predictor of the temporal properties of pulmonary technosphere insulin in humans. In: Dalby RN, Byron PR, Peart J, Farr SJ, eds. Respiratory Drug Delivery VII. Raleigh, NC: Davis Horwood International Publishing; 2000;463–465.

Brown LR, Rashba-Step J, Scott T, et al. Pulmonary delivery of novel insulin microspheres. In: Dalby RN, Byron PR, Peart J, Farr SJ, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing; 2002;431–433.

Blair J, Coghlan D, Langner E, Jansen M, Askey-Sarvar A. Sustained delivery of insulin via the lung using Solidose technology. In: Dalby RN, Byron PR, Peart J, Farr SJ, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing; 2002;411–413.

Edwards DE, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol. 1997;84(2):379–385.

Edwards DE, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997;276:1868–1871.

Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16(11):1735–1742.

Morcol T, Nagappan P, He Q, Bell SJD Utilizing calcium phosphate particles as drug delivery vehichles for therapeutic proteins, IIR-USA, ed. IIR-USA 1 st Annual Protein and Peptide Formulation Strategies, August 19–21, 2002; 9–15.

Yeh MK, Jenkins PG, Davis SS, Coombes AGA. Improving the delivery capacity of microparticle system using blends of poly(DL-lactide co-glycolide) and poly(ethylene glycol). J Control Release 1995;37:1–9.

Gehrke SH, Uhden LH, McBride JF. Enhanced loading and activity retention of bioactive proteins in hyrdogel delivery systems. J Control Release 1998;55:21–33.

Rocci ML, Jusko WL. LAGRAN program for area and moments in pharmacokinetics. Comp Prog Biomed. 1983;16:203–211.

Garcia-Contreras L, Morcol T, Bell SJD, Hickey AJ. Evaluation of novel calcium phosphate particles as pulmonary delivery systems for insulin in rats. AAPS Pharm Sci (Suppl) 2001;3(3). 0683 0271 V

Cefalu WT, Balagtas CC, Landschultz WH, Gelfand RA. Sustained efficacy and pulmonary safety of inhaled insulin during 2 years of outpatient therapy. Diabetes 2000;49(Suppl 1):A406.

He Q, Mitchell AR, Johnson SL, Wagner-Bartak C, Morcol T, Bell SJD. Calcium phosphate nanoparticle adjuvant. Clin Diagnos Lab Immunol. 2000;7:899–903.

Gonda I. Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels. J Pharm Sci 1988;77(4):340–346.

Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev 1999;35:235–247.

Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001;44:305–308.

Hoffman A, Ziv E. Pharmacokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet. 1997;33(4):285–301.

Rave K, Heise T, Pfutzner A, Steiner SS, Heinemann L. Assesment of dose-reponse characteristics for a new pulmonary insulin formulation and an inhaler. Exp Clin Endocrinol Diabetes 2000;108(Suppl. 1):S161.

Steiner SS, Rave K, Heise T, et al. Pharmacokinetic properties and bioavailability of inhaled dry powder Technosphere TM/Insulin. Exp Clin Endocrinol Diabetes 2000;108(Suppl. 1):S161.

Steiner SS, Pfutzner A, Wilson B, Harzer O, Heinemann L, Rave K. Technosphere TM/Insulin: proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17–21.

Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin absorption from solution and aerosol by rat lung. Int J Pharm. 1992;88:63–73.

Komada F, Iwakawa S, Yamamoto N, Sakakibara H, Okumura K. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lungs. J Pharm Sci 1994;83:863–867.

Kawashima Y, Yamamoto H, Takeguchi H, Fujioka S, Hino T. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release. 1999;62:279–287.

Morimoto K, Metsugi K, Katsumata H, Iwanaga K, Kakemi M. Effects of low viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev Ind Pharm. 2001;27(4):365–371.

Scott T, Sullivan A, Proos R, et al. Novel technology for fabrication of therapeutic microspheres for pulmonary delivery. In: Dalby RN, Byron PR, Peart J, Farr SJ, eds. Respiratory Drug Delivery VIII. Raleigh, NC: Davis Horwood International Publishing; 2002;435–437.